Atherosklerose: Open Access

Abstrakt

Immune Checkpoint Inhibitors and Atherosclerosis: Emerging Insights and Therapeutic Implications

Lin Xu

As the use of immune checkpoint inhibitors (ICIs) expands in clinical practice, our understanding of their potential adverse effects continues to grow. Arising substantiation indicates a connection between ICI remedy and an increased threat of accelerated atherosclerosis and atherosclerotic cardiovascular (CV) events. In this discussion, we delve into the biological plausibility and clinical evidence supporting the impact of immune checkpoint inhibition on the development of atherosclerotic CV disease. Additionally, we offer insights on potential diagnostic and pharmacological strategies aimed at mitigating atherosclerotic risk in patients receiving ICI treatment. Although our comprehension of the pathophysiology of ICI-related atherosclerosis is in its early stages, further research is warranted to unravel the underlying mechanisms linking ICI therapy to atherosclerosis. Leveraging the valuable insights provided by ICI therapy into CV biology, it is crucial to develop robust approaches to effectively manage the growing population of patients who may face an increased risk of atherosclerotic CV disease.